Paper7585585
Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta.
Wali RK and 9 others. Cancer Res, 1995. Cited by 86 papers, by iCite.
Cite this record
ConductScience Library. Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta. Papers, record 7585585. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7585585
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anticarcinogenic Agents | Major topic |
| Colonic Neoplasms | Major topic |
| Isoenzymes | Major topic |
| Protein Kinase C | Major topic |
| Ursodeoxycholic Acid | Major topic |
| Animals | |
| Azoxymethane | |
| Cholic Acid | |
| Cholic Acids | |
| Male | |
| Rats | |
| Rats, Inbred F344 |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA 36745 | NCI NIH HHS | United States | R01CA036745 | PubMed and NIH | NIH RePORTER |
| CA 41108 | NCI NIH HHS | United States | P01CA041108 | PubMed and NIH | NIH RePORTER |
| DK 42086 | NIDDK NIH HHS | United States | P30DK042086 | PubMed and NIH | NIH RePORTER |
| R37CA036745 | NIH | NIH RePORTER |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 86 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41051952 | Hepatic protein kinase Cβ antagonizing p38MAPK to activate ERK1/2 to dysregulate biliary lipid composition upon lithogenic stress. | Am J Physiol Gastrointest Liver Physiol | 2025 | https://conductscience.org/library/papers/41051952 | PubMed |
| 26939849 | Consequences of bile salt biotransformations by intestinal bacteria. | Gut Microbes | 2016 | https://conductscience.org/library/papers/26939849 | PubMed |
| 26770670 | A review of the medical treatment of primary sclerosing cholangitis in the 21st century. | Ther Adv Chronic Dis | 2016 | https://conductscience.org/library/papers/26770670 | PubMed |
| 24852569 | In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. | Am J Physiol Gastrointest Liver Physiol | 2014 | https://conductscience.org/library/papers/24852569 | PubMed |
| 24799986 | Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. | World J Hepatol | 2014 | https://conductscience.org/library/papers/24799986 | PubMed |
| 22785210 | C1B domain peptide of protein kinase Cγ significantly suppresses growth of human colon cancer cells in vitro and in an in vivo mouse xenograft model through induction of cell cycle arrest and apoptosis. | Cancer Biol Ther | 2012 | https://conductscience.org/library/papers/22785210 | PubMed |
| 22475628 | Down-regulation of PKCζ in renal cell carcinoma and its clinicopathological implications. | J Biomed Sci | 2012 | https://conductscience.org/library/papers/22475628 | PubMed |
| 21556038 | High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. | Am J Gastroenterol | 2011 | https://conductscience.org/library/papers/21556038 | PubMed |
| 20729391 | Mechanistic insight into the ability of American ginseng to suppress colon cancer associated with colitis. | Carcinogenesis | 2010 | https://conductscience.org/library/papers/20729391 | PubMed |
| 20194350 | Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor. | Carcinogenesis | 2010 | https://conductscience.org/library/papers/20194350 | PubMed |
| 19446582 | Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR. | Biochim Biophys Acta | 2009 | https://conductscience.org/library/papers/19446582 | PubMed |
| 16434969 | Protein kinase C delta inhibits Caco-2 cell proliferation by selective changes in cell cycle and cell death regulators. | Oncogene | 2006 | https://conductscience.org/library/papers/16434969 | PubMed |
| 11856477 | Chemoprevention of N-methylnitrosourea-induced colon carcinogenesis by ursodeoxycholic acid-5-aminosalicylic acid conjugate in F344 rats. | Jpn J Cancer Res | 2002 | https://conductscience.org/library/papers/11856477 | PubMed |
| 10330400 | Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. | J Cell Biol | 1999 | https://conductscience.org/library/papers/10330400 | PubMed |
| 9849578 | Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. | Jpn J Cancer Res | 1998 | https://conductscience.org/library/papers/9849578 | PubMed |
| 9824590 | Chemoprevention of colorectal cancer. | Gut | 1998 | https://conductscience.org/library/papers/9824590 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7585585
GET https://conductscience.org/api/papers/v1/7585585/authors